ING Group’s TherapeuticsMD TXMD Stock Holding History

ING Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,092	Closed	-$996K	–	842
2019 Q1	$996K	Buy	4,092 +360	+10%	+$95.3K	0.02%	321
2018 Q4	$711K	Sell	3,732 -1,371	-27%	-$334K	0.02%	396
2018 Q3	$1.67M	Sell	5,103 -260	-5%	-$79.7K	0.03%	274
2018 Q2	$1.67M	Sell	5,363 -200	-4%	-$61.1K	0.03%	242
2018 Q1	$1.35M	Buy	5,563 +184	+3%	+$51.6K	0.02%	273
2017 Q4	$1.63M	Buy	5,379 +20	+0.4%	+$5.57K	0.03%	254
2017 Q3	$1.42M	Buy	5,359 +3,380	+171%	+$977K	0.03%	262
2017 Q2	$522K	Buy	1,979 +1,000	+102%	+$250K	0.01%	479
2017 Q1	$353K	Buy	+979	New	+$303K	0.01%	492

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ING Group's TXMD Position: Q2 2019 in Review

ING Group sold out of TherapeuticsMD (TXMD) in Q2 2019, closing a stake of 4,092 shares — an estimated $996K sold.

ING Group first reported a position in TXMD in Q1 2017 and held it in 9 quarters. The position peaked at $1.67M in Q3 2018. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

ING Group reported no remaining TherapeuticsMD position as of Q2 2019 after selling out during the quarter.
ING Group sold 4,092 TherapeuticsMD shares in Q2 2019, an estimated $996K.
ING Group first reported a position in TherapeuticsMD in Q1 2017 and held it in 9 quarters.
ING Group's TherapeuticsMD position peaked at $1.67M in Q3 2018.
148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on ING Group's 13F filing for Q2 2019, filed 12 Aug 2019.